These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2462300)

  • 21. Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate.
    Breslin D; Fields DW; Chou TC; Marion DN; Kane M; Vaughan ED; Felsen D
    J Urol; 1993 Feb; 149(2):395-9. PubMed ID: 7678872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia.
    Pool JL
    Br J Clin Pract Suppl; 1994 May; 74():13-7. PubMed ID: 7519436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with alpha-adrenoceptor antagonists in benign prostatic hypertrophy.
    Caine M
    Fed Proc; 1986 Oct; 45(11):2604-8. PubMed ID: 2428670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha blockade for the treatment of benign prostatic hyperplasia.
    Lepor H
    Urol Clin North Am; 1995 May; 22(2):375-86. PubMed ID: 7539182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Terazosin in the treatment of benign prostatic hypertrophy].
    Andres M; De Cobelli O; Carmignani L; Musci R; Kocjancic E; Panizzutti M; Rocco F
    Arch Ital Urol Androl; 1995 Feb; 67(1):37-9. PubMed ID: 7538386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
    Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
    J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
    Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
    Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of alpha blockers in BPH.
    Jardin A
    Prog Clin Biol Res; 1994; 386():279-83. PubMed ID: 7528395
    [No Abstract]   [Full Text] [Related]  

  • 30. [Autonomic nervous system and prostatic physiology. Specific features of the alpha-adrenergic system].
    Mottet N; Costa P; Bali JP
    Prog Urol; 1999 Feb; 9(1):26-36. PubMed ID: 10212950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
    Chapple CR
    BJU Int; 2004 Sep; 94(5):738-44. PubMed ID: 15329091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The mechanism of action of the alpha-adrenoblocker prazosin on bladder function in patients with benign prostatic hyperplasia].
    Loran OB; Vishnevskiĭ AE
    Urol Nefrol (Mosk); 1997; (4):19-22. PubMed ID: 9381614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Alpha adrenergic blocking agents in disorders of the bladder sphincter].
    Perrigot M; Vannier A; Bor Y
    Rev Prat; 1986 Jan; 36(5):223-8. PubMed ID: 2421393
    [No Abstract]   [Full Text] [Related]  

  • 34. Medical management of prostatic diseases.
    Schlegel PN
    Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
    Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
    Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical overview of prazosin in the treatment of prostatic obstruction.
    Milroy E
    Urol Int; 1990; 45 Suppl 1():1-3. PubMed ID: 1690474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-1 receptor mediated smooth muscle regulation in benign prostatic hyperplasia.
    Drescher P; Eckert RE; Sparwasser C; Madsen PO
    Scand J Urol Nephrol Suppl; 1994; 157():33-40. PubMed ID: 7524142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The place of pharmacologic treatment in benign prostatic hyperplasia.
    Caine M
    Semin Urol; 1985 Nov; 3(4):311-6. PubMed ID: 2441447
    [No Abstract]   [Full Text] [Related]  

  • 39. Current treatment of BPH.
    Roylance P; Gibelin B; Espié J
    Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment and pharmacologic management of BPH in the context of common comorbidities.
    O'Leary MP
    Am J Manag Care; 2006 Apr; 12(5 Suppl):S129-40. PubMed ID: 16613527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.